NTRK3 and amyotrophic lateral sclerosis: The poor specificity of NT-3 (binding to multiple receptors TrkC-FL, p75NTR, TrkC.T1), poor pharmacokinetics (circulation half-life under 2 minutes), and the inability to reach the different pools of receptors make NT-3 a poor therapeutic agent for ALS.